Kessler Topaz Meltzer & Check, LLP - Class Action Announcement for Ultragenyx Pharmaceutical Inc. Investors: A Securities Fraud Class Action Lawsuit Was Filed Against Ultragenyx Pharmaceutical Inc.

Core Viewpoint - A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly misleading investors regarding the efficacy of its drug, setrusumab, during the specified class period [2][3][5]. Group 1: Lawsuit Details - The lawsuit is filed on behalf of investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025 [2][5]. - The case is titled Bailey v. Ultragenyx Pharmaceutical Inc., et al, and is being heard in the United States District Court for the Northern District of California [2]. - Investors have until April 6, 2026, to file for lead plaintiff status [2][5]. Group 2: Allegations - The complaint alleges that Ultragenyx made false and misleading statements about the reliability of information regarding setrusumab's effects on Osteogenesis Imperfecta patients [3]. - It is claimed that Ultragenyx downplayed the risks associated with the Phase III Orbit study, which may not have achieved a statistically significant reduction in annualized fracture rate [3]. - The lawsuit asserts that the company's positive statements about its business and prospects were materially misleading and lacked a reasonable basis [3]. Group 3: Investor Actions - Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for recovery options at no cost [5][6]. - Investors can file to be lead plaintiff by the April 6, 2026 deadline or choose to remain absent from the class [6]. - The law firm offers a free case evaluation for investors who experienced losses related to Ultragenyx [6][7].